Steroid injections may slow diabetes-related eye disease

December 24, 2009

Researchers led by specialists at the Johns Hopkins Wilmer Eye Institute have found that injecting a corticosteroid, triamcinolone, directly into the eye may slow the progression of proliferative diabetic retinopathy, a complication of diabetes that frequently leads to blindness.

Authors of the study caution, however, that because use of steroids in the eye may increase the risk of glaucoma and cataract, laser photocoagulation remains the treatment of choice until further development of drugs that may reproduce the good effects of steroids, without the damage.

"Steroid treatment worked, but because of safety issues, cannot be recommended routinely at this time," says Neil M. Bressler, the James P. Gills Professor of Ophthalmology and chief of the Retina Division of the Johns Hopkins Wilmer Eye Institute, chair of the government-sponsored Diabetic Retinopathy Clinical Research Network. "It is a condition that can be treated safely and effectively with lasers."

The study, published in the December issue of the Archives of Ophthalmology, described and compared one of two treatments on 840 eyes from 693 men and women between July 2004 and May 2006. The subjects, about evenly divided between men and women with an average age of 63, had diabetic retinopathy with macular edema, a swelling of the central portion of the retina that's caused by leakage of fluid.

Proliferative diabetic retinopathy is marked by the growth of new and unwanted blood vessels on the optic nerve in the back of the eye (which communicates information from the retina to the brain) or another area of the retina, the light-sensitive part of the eye. Despite advances in treating both diabetes and its complications, about 700,000 Americans have proliferative diabetic retinopathy and 63,000 new cases develop each year.

In the study, each patient's eyes were randomly assigned to receive either a laser treatment (photocoagulation) for diabetic macular edema or an injection (1 or 4 milligrams) of triamcinolone acetonide directly into the eye as often as every four months.

According to Bressler, lead author of the study, there was some evidence that steroids could improve vision outcomes from diabetic macular edema (DME), swelling of the center of the retina, the part of the retina used for reading or driving. Study results showed that steroids were not superior to laser treatments for DME.

"The primary objective of the study was to determine if steroids were superior to laser for DME, and if so, to balance that superiority with steroids' side effects. A secondary objective was to determine if the steroids affected the progression of diabetic retinopathy," adds Bressler. "Steroid treatments did reduce the risk of progression of diabetic retinopathy, but, not DME, which can also cause vision loss from proliferative diabetic retinopathy, bleeding in the middle cavity of the eye or scarring of the retina, which can detach the retina from the back wall of the eye."

The steroid injections were not superior to laser with respect to increasing the chance of improved vision and decreasing the chance of vision loss, the primary objective of a study reported in 2008. "However, there was evidence that steroids can affect the pathways that lead to the development of new blood vessels on the surface of the retina in diabetes, a secondary objective of the study" says Bressler. "Controlling blood glucose levels can help prevent the development of retinopathy and laser treatments can reduce the risk of vision loss, but the identification of other treatments remains important."

Bressler and colleagues, in the Diabetic Retinopathy Clinical Research (DRCR) Network, discovered that after two years, retinopathy had progressed in 31 percent of 330 eyes treated with laser treatment, 29 percent of 256 eyes treated with 1-milligram doses of triamcinolone acetonide, and 21 percent of 254 eyes treated with 4-milligram doses. The differences appeared to be sustained at three years, even though most eyes in the triamcinolone groups did not receive injections every four months during the second year and less than half received any injections in the third year because there no longer was macular edema, or less commonly, because side effects from the injections precluded applying additional steroids when following the study's treatment protocol.

Bressler says the study suggests that corticosteroids interfere with the creation of new blood vessels by reducing the production of compounds that spur their growth and cautions that steroids are also associated with other eye diseases. "Researchers now need to find ways of using the steroid effect on these blood vessels for treatment, but, not at the expense of causing glaucoma and the side effects of cataract formation or worsening of cataracts which could lead to the need for a patient to undergo cataract surgery."
-end-
Other investigators who authored the study for the Diabetic Retinopathy Clinical Research Network include Allison R. Edwards, M.S., Roy W. Beck, M.D., Ph.D., Christina J. Flaxel, M.D., Adam R. Glassman, M.S., Michael S. Ip, M.D., Craig Kollman, Ph.D., Baruch D. Kuppermann, M.D., and Thomas W. Stone, M.D.

The study was supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, part of the Department of Health and Human Services. Allergan Inc. provided the preservative-free triamcinolone acetonide and topical antibiotics as requested by the DRCR Network and unrestricted funds to the DRCR Network. Following the Network's Industry Collaboration Guidelines to maintain academic integrity, the DRCR Network had complete control over the design of the protocol, ownership of the data and all editorial content of presentation and publications related to the protocol.

On the Web:

Wilmer Eye Institute
http://www.hopkinsmedicine.org/wilmer/

DRCR Network
http://public.drcr.net/ViewPage.aspx?PageName=Home

National Eye Institute
http://www.nei.nih.gov/

Johns Hopkins Medicine

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.